search
Back to results

Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II

Primary Purpose

Contraceptive Usage, Opioid Dependence

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Treatment as usual
WHO contraception protocol
Incentives
Sponsored by
University of Vermont
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Contraceptive Usage focused on measuring Contraception, Unintended pregnancy, HIV risk, Sexually transmitted infections, Women, Pregnancy, Neonatal health, Drug use, Drug treatment, Opioids

Eligibility Criteria

18 Years - 44 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • 18-44 years of age
  • pre-menopausal and have no history of tubal ligation or hysterectomy
  • have had heterosexual vaginal sex in the past 3 months
  • have no plans to become pregnant in the next 6 months
  • be medically eligible to use prescription contraceptives
  • report no prescription contraceptive use (i.e., no use of pill, patch, ring, implants, or IUDs in the past 7 days or injections in the past 3 months)
  • be in opioid maintenance treatment
  • at least 8 weeks postpartum
  • not be facing imminent incarceration
  • have no plans to leave the area in the next 12 months
  • be English-speaking

Exclusion Criteria:

  • failure to meet the aforementioned inclusion criteria
  • refusal to participate

Sites / Locations

  • Vermont Center on Behavior and Health

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Treatment as usual

WHO contraception protocol

WHO contraception protocol + incentives

Arm Description

The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.

The WHO contraception protocol condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits.

The WHO + incentives condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits, but will also receive financial incentives contingent on attending those follow-up visits.

Outcomes

Primary Outcome Measures

Percentage of Participants With Verified Prescription Contraceptive Use at the 6-month Assessment

Secondary Outcome Measures

Full Information

First Posted
April 2, 2015
Last Updated
January 19, 2023
Sponsor
University of Vermont
search

1. Study Identification

Unique Protocol Identification Number
NCT02411357
Brief Title
Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II
Official Title
Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
May 5, 2015 (Actual)
Primary Completion Date
March 6, 2019 (Actual)
Study Completion Date
September 9, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Vermont

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Nearly 9 of every 10 pregnant opioid-dependent women report that the current pregnancy was unintended and the majority of non-pregnant opioid-maintained women do not use contraception or use less effective methods like condoms. This proposal aims to further test a novel contraceptive management program to increase use of more effective contraceptives among opioid-maintained women at risk of unintended pregnancy.
Detailed Description
The rate of unintended pregnancy among opioid-dependent women is extremely high: nearly 9 of every 10 pregnant opioid-dependent women report that the current pregnancy was unintended, a rate 2-3 times that of the general population. Despite these dire statistics, there is a dearth of scientific knowledge about contraceptive use in this population and about how to promote use of more effective contraceptives (e.g., birth control pills, intrauterine devices (IUDs), implants). The aim of this Stage II Behavioral and Integrative Treatment Development Program application is to further test a novel contraceptive management program to increase use of more effective contraceptives among opioid-maintained (OM) women. OM women at risk for unintended pregnancy (N=195) will be randomly assigned to one of three conditions: (1) usual care, (2) the World Health Organization (WHO) contraception protocol, and (3) the WHO contraception protocol + financial incentives. Participants in the usual care condition will receive a referral to local contraceptive providers. Participants in the WHO alone condition will receive the WHO contraceptive initiation protocol and their choice of prescription contraceptive in consultation with a nurse practitioner. These participants will also subsequently be offered the opportunity to attend 13 follow-up visits where vital signs and a urine pregnancy test will be administered. Side effects of any prescription contraception will also be assessed and participants will have the option to change their prescription contraceptive method at any time. Participants in the WHO + incentives condition will also receive the WHO contraceptive initiation protocol and their choice of prescription contraceptive in consultation with a nurse practitioner. These participants will also subsequently be offered the opportunity to attend 13 follow-up visits where vital signs and a urine pregnancy test will be administered. Side effects of any prescription contraception will be assessed and participants will have the option to change their prescription contraceptive method at any time. Participants in the WHO + incentives condition participants will also earn vouchers exchangeable for goods and services for attending these visits. Contraceptive use by all participants will be evaluated at assessments scheduled 1, 3, 6, and 12 months after trial intake.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Contraceptive Usage, Opioid Dependence
Keywords
Contraception, Unintended pregnancy, HIV risk, Sexually transmitted infections, Women, Pregnancy, Neonatal health, Drug use, Drug treatment, Opioids

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
138 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment as usual
Arm Type
Active Comparator
Arm Description
The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
Arm Title
WHO contraception protocol
Arm Type
Experimental
Arm Description
The WHO contraception protocol condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits.
Arm Title
WHO contraception protocol + incentives
Arm Type
Experimental
Arm Description
The WHO + incentives condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits, but will also receive financial incentives contingent on attending those follow-up visits.
Intervention Type
Behavioral
Intervention Name(s)
Treatment as usual
Intervention Description
General information about contraceptive options and referral to contraceptive service providers
Intervention Type
Behavioral
Intervention Name(s)
WHO contraception protocol
Intervention Description
World Health Organization's contraception protocol
Intervention Type
Behavioral
Intervention Name(s)
Incentives
Intervention Description
Financial incentives contingent on follow-up visit attendance
Primary Outcome Measure Information:
Title
Percentage of Participants With Verified Prescription Contraceptive Use at the 6-month Assessment
Time Frame
6 months after randomization

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
44 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18-44 years of age pre-menopausal and have no history of tubal ligation or hysterectomy have had heterosexual vaginal sex in the past 3 months have no plans to become pregnant in the next 6 months be medically eligible to use prescription contraceptives report no prescription contraceptive use (i.e., no use of pill, patch, ring, implants, or IUDs in the past 7 days or injections in the past 3 months) be in opioid maintenance treatment at least 8 weeks postpartum not be facing imminent incarceration have no plans to leave the area in the next 12 months be English-speaking Exclusion Criteria: failure to meet the aforementioned inclusion criteria refusal to participate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sarah H. Heil, Ph.D.
Organizational Affiliation
University of Vermont
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vermont Center on Behavior and Health
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
34259798
Citation
Heil SH, Melbostad HS, Matusiewicz AK, Rey CN, Badger GJ, Shepard DS, Sigmon SC, MacAfee LK, Higgins ST. Efficacy and Cost-Benefit of Onsite Contraceptive Services With and Without Incentives Among Women With Opioid Use Disorder at High Risk for Unintended Pregnancy: A Randomized Clinical Trial. JAMA Psychiatry. 2021 Oct 1;78(10):1071-1078. doi: 10.1001/jamapsychiatry.2021.1715.
Results Reference
derived

Learn more about this trial

Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II

We'll reach out to this number within 24 hrs